Open AccessBeneficial Effects of Angiotensin II Type 1 Receptor Blocker Antihypertensive Treatment on Inflammation Indices: The Effect of Smoking
Author(s) -
Kyvelou StellaMaria G.,
Vyssoulis Gregory P.,
Karpanou Eva A.,
Adamopoulos Dionysios N.,
Gialernios Theodoros P.,
Pietri Panagiota G.,
Cokkinos Dennis V.,
Stefanadis Christodoulos I.
Publication year - 2007
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2007.05819.x
Subject(s) - medicine , diuretic , blood pressure , endocrinology , angiotensin receptor , renal function , c reactive protein , population , inflammation , angiotensin ii , gastroenterology , environmental health
The effect of long‐term angiotensin II type 1 receptor blocker (ARB) therapy on inflammation indices has not been fully investigated in a hypertensive population. The authors evaluated 323 consecutive nondiabetic patients (mean age, 57 years; 176 men; 92 smokers) with high renin activity and uncomplicated essential hypertension whose blood pressure levels normalized (from 163.9/100.7 mm Hg to 131.6/82.8 mm Hg) after 4 weeks of ARB or ARB/diuretic treatment. All patients underwent full laboratory evaluation (routine examination of blood and urine, liver, kidney, thyroid function, and lipid and glucose profiles), including measurement of high‐sensitivity C‐reactive protein and serum amyloid A levels, at drug‐free baseline, which was repeated after 6 months of ARB or ARB/diuretic treatment. A significant (P<.001) overall decrease was noted in both high‐sensitivity C‐reactive protein (−0.41±1.56 mg/dL) and serum amyloid A (−0.62±2.03 mg/dL), but a smaller decrease in high‐sensitivity C‐reactive protein and serum amyloid A change was seen in the smoker subgroup compared with nonsmokers (P<.05), indicating that the ARB or ARB/diuretic anti‐inflammatory effect may be adversely affected by smoking status.